Therefore, as whole blood staining of fresh blood is becoming more standard practice, this will no doubt improve the prospect of using CD14+HLADRlo/neg monocytes as a biomarker for understanding responses to cancer immunotherapy. The gene discussed is CD14; the disease is cancer.